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INTRODUCTION 
Chronic liver disease in the clinical context is a disease process 
of the liver that involves a process of progressive destruction and 
regeneration of the liver parenchyma leading to fibrosis and cirrhosis. 
Cirrhosis  is a consequence of chronic liver disease characterized by 
replacement  of liver tissue by fibrosis, scar tissue and regenerative 
nodules (lumps that occur as a result of a process in which damaged 
tissue is regenerated)[52][53] leading to loss  of liver function. Cirrhosis is 
most commonly caused by alcoholism, hepatitis B and C, and fatty liver 
disease, but has many other possible causes. Some cases are  idiopathic, 
i.e., of unknown cause. Ascites (fluid retention in the abdominal cavity) 
is the most common complication  of cirrhosis, and is associated with a 
poor quality of life, increased risk of  infection, and a poor long-term 
outcome. Other potentially life-threatening complications are hepatic 
encephalopathy (confusion and coma) and bleeding from esophageal 
varices. Cirrhosis is generally irreversible, and treatment usually 
focuses on preventing progression and complications. In advanced 
stages of  cirrhosis the only option is a liver transplant. 
The word "cirrhosis" derives from Greek word  κίρῥος, meaning 
tawny (the orange- yellow colour of the diseased liver). While the 
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clinical entity was known before, it was René Laennec who gave it the 
name "cirrhosis" in his 1819 work in which he also describes the 
stethoscope.[56] 
                                                CAUSES FOR CIRRHOSIS 
Cirrhosis has many possible causes; sometimes more than one 
cause is present in  the same patient. In the Western World, chronic 
alcoholism and hepatitis C,  While in India alcoholism and hepatitis B 
are the  most common causes. 
• Alcoholic liver disease (ALD). Alcoholic cirrhosis develops for 
between 10% and 20% of individuals who drink heavily for a 
decade or more.(54) Alcohol seems to injure the liver by blocking 
the normal metabolism of protein, fats, and carbohydrates. 
Patients may also have concurrent alcoholic hepatitis with fever, 
hepatomegaly, jaundice, and anorexia. AST and ALT are both 
elevated but less than 300 IU/L with a AST:ALT ratio > 2.0, a 
value rarely seen in other liver diseases. Liver biopsy may show 
hepatocyte necrosis, Mallory bodies, neutrophilic infiltration with 
perivenular inflammation.  
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• Chronic hepatitis C. Infection with the hepatitis C virus causes 
inflammation of the liver and a variable grade of damage to the 
organ that over several decades can lead to cirrhosis. Cirrhosis 
caused by hepatitis C is the most common reason for liver 
transplant. Can be diagnosed with serologic assays that detect 
hepatitis C antibody or viral RNA. The enzyme immunoassay, 
EIA-2, is the most commonly used screening test in the US.  
• Chronic hepatitis B. The hepatitis B virus causes liver 
inflammation and injury that over several decades can lead to 
cirrhosis. Hepatitis D is dependent on the presence of hepatitis B 
and accelerates cirrhosis in  co-infection. Chronic hepatitis B can 
be diagnosed with detection of HBsAg  over 6 months after 
initial infection. HBeAg and HBV DNA are determined to assess 
whether patient will need antiviral therapy.  
• Non-alcoholic steatohepatitis (NASH). In NASH, fat builds up in 
the liver and eventually causes scar tissue. This type of hepatitis 
appears to be associated with diabetes, protein malnutrition, 
obesity, coronary artery disease, and treatment with 
corticosteroid medications. This disorder is similar to that of 
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alcoholic liver disease but patient does not have an alcohol 
history. Biopsy is needed for diagnosis.  
• Primary biliary cirrhosis. Pt may be asymptomatic or  may 
complain of fatigue, pruritus, and skin hyperpigmentation with 
hepatomegaly. There is prominent alkaline phosphatase elevation 
as well as elevations in cholesterol and bilirubin. Gold standard 
diagnosis is antimitochondrial antibodies with liver biopsy as 
confirmation if showing florid bile duct lesions. It is more 
common in women.  
• Primary sclerosing cholangitis. PSC is a progressive cholestatic 
disorder presenting with pruritus, steatorrhea, fat soluble vitamin 
deficiencies, and metabolic bone disease. There is a strong 
association with inflammatory bowel disease (IBD), especially 
ulcerative colitis. Diagnosis is best with contrast cholangiography 
showing diffuse, multifocal strictures and focal dilatation of bile 
ducts, leading to a beaded appearance. Non-specific serum 
immunoglobulins may also be elevated.  
• Autoimmune hepatitis. This disease is caused by the 
immunologic damage to the liver causing inflammation and 
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eventually scarring and cirrhosis. Findings include elevations in 
serum globulins, especially gamma globulins. Therapy with 
prednisone and/or azathioprine is beneficial. Cirrhosis due to 
autoimmune hepatitis still has 10-year survival of 90%+. There is 
no specific tool to diagnose autoimmune hepatitis  but it can be 
beneficial to initiate a trial of corticosteroids.  
• Hereditary hemochromatosis. Usually presents with family 
history of cirrhosis, skin hyperpigmentation, diabetes mellitus, 
pseudogout, and/or cardiomyopathy, all due to signs of iron 
overload. Labsoratory investigations will show fasting transferrin 
saturation of > 60% and ferritin > 300 ng/mL. Genetic testing 
may be used to identify HFE mutations. If these are present, 
biopsy may not need to be performed. Treatment is with 
phlebotomy to lower total body iron levels.  
• Wilson's disease. Autosomal recessive disorder characterized by 
low serum ceruloplasmin and increased hepatic copper content 
on liver biopsy. Patient may also have Kayser-Fleischer rings in 
the cornea and altered mental status.  
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• Alpha 1-antitrypsin deficiency (AAT). Autosomal recessive 
disorder. Patients may also have emphysema , especially if they 
have a history of tobacco smoking. Serum AAT levels are low. 
Recombinant AAT is used to prevent lung disease due to AAT 
deficiency.  
• Cardiac cirrhosis. Due to chronic right sided heart failure which 
leads to liver congestion.  
• Galactosemia  
• Glycogen storage disease type IV  
• Cystic fibrosis  
• Hepatotoxic drugs or toxins  
• Certain parasitic infections (such as schistosomiasis)  
GRADING    
The severity of cirrhosis is commonly classified with the Child- 
Pugh score. This score uses bilirubin, albumin, INR, presence and 
severity of ascites and encephalopathy to classify patients in class A, 
B or C; class A has favourable prognosis, while class C is at high 
risk of death. It was devised in 1964 by Child and Turcotte and 
modified in 1973 by Pugh et al..[55] 
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More modern scores, used in the allocation of liver transplants 
but also in other contexts, are the Model for End-Stage Liver Disease 
(MELD) score and its pediatric counterpart, the Pediatric End-Stage 
Liver Disease (PELD) score. The hepatic venous pressure gradient, i.e., 
the difference in venous pressure between afferent and efferent blood to 
the liver, also determines severity of cirrhosis, although hard to 
measure. A value of 16 mm or more means a great  increased   risk of 
dying.[57] 
COMPLICATIONS 
As the disease progresses, complications may develop. In some 
people, these may  be the first signs of the disease. 
• Bruising and bleeding resulting from decreased production of 
coagulation factors.  
• Jaundice as a result of decreased processing of bilirubin.  
• Itching (pruritus) because of bile salts products deposited in the 
skin.  
• Hepatic encephalopathy - the liver does not clear ammonia and 
related nitrogenous substances from the blood, which are carried 
to the brain, affecting cerebral functioning: feeling to neglect of 
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personal appearance, unresponsiveness, forgetfulness, trouble 
concentrating, or changes in sleep habits.  
• Sensitivity to medication caused by decreased metabolism of the 
active compounds.  
• Hepatocellular carcinoma is primary liver cancer, a frequent 
complication of cirrhosis. It has a high mortality rate.  
• Portal hypertension - blood normally carried from the intestines 
and spleen through the hepatic portal vein flows more slowly and 
the pressure increases; this leads to the following complications:  
o Ascites - fluid leaks through the vasculature into the 
abdominal cavity.  
o Esophageal varices - collateral portal blood flow through 
vessels in the stomach and esophagus. These blood vessels 
may become enlarged and are more likely to burst.  
• Problems in other organs.  
o Cirrhosis can cause immune system dysfunction, leading 
to infection. Signs and symptoms of infection may be 
aspecific are more difficult to recognize (e.g., worsening 
encephalopathy but no fever).  
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o Fluid in the abdomen (ascites) may become infected with 
bacteria normally present in the intestines ie., SBP  
(spontaneous bacterial peritonitis).  
o Hepatorenal syndrome - insufficient blood supply to 
the kidneys, causing acute renal failure. This 
complication has a very high mortality (over 50%).  
o Hepatopulmonary syndrome - blood bypassing the normal 
lung circulation (shunting), leading to cyanosis and 
dyspnea (shortness of breath), characteristically worse on 
sitting up.[1]  
o Portopulmonary hypertension - increased blood pressure 
over the lungs as a consequence of portal hypertension.[1]  
o Portal hypertensive gastropathy which refers to changes in 
the mucosa of the stomach in patients with portal 
hypertension, and is associated with cirrhosis severity. 
Hepatorenal syndrome (HRS) is the development of  renal failure 
in patients with advanced chronic liver  disease, occasionally fulminant 
hepatitis, who have portal  hypertension and ascites. Estimates indicate 
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that at least  40% of patients with cirrhosis and ascites will develop  
HRS during the natural history of their disease.  
During the 19th century, Frerichs and Flint (31) made the original 
description of renal function  disturbances in liver disease. They 
described oliguria  in  patients with chronic liver disease in the absence 
of  proteinuria and linked the  abnormalities in renal function  to 
disturbances present in the systemic circulation.  In  the 1950s, the 
clinical description of  HRS by Sherlock,  Popper, and Vessin(18) 
emphasized the functional nature of  the syndrome, the coexistence of 
systemic  circulatory  abnormalities, and its dismal prognosis. Further 
studies  in the  following  two  decades demonstrated that renal  failure 
occurred because of  vasoconstriction  of  the renal   circulation and 
intense systemic arteriolar  vasodilatation  resulting  in  reduced 
systemic vascular resistance and  hypotension.  
In HRS, the histological appearance  of the kidneys is normal, 
and  the kidneys  often  resume  normal function following liver 
transplantation  in most  cases except 1-7% as mentioned  later. This  
makes HRS a unique  pathophysiological disorder that  provides 
possibilities for  studying the interplay between  vasoconstrictor and 
vasodilator systems on the  renal  circulation.2  
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THERE ARE TWO WELL-DIFFERENTIATED CLINICAL PATTERNS OF 
HEPATO RENAL SYNDROME 
TYPE 1 HEPATO RENAL SYNDROME 
• Characterized by rapid and progressive impairment of renal 
function defined as a doubling of the initial serum creatinine to a 
level greater than 2.5 mg/dl or a 50% reduction of the initial  
24-hour creatinine clearance to  a level lower than 20 ml/min in 
less than 2 weeks.  
• Usually occurs in severe liver failure (Jaundice, encephalopathy, 
and coagulopathy) 
• Occurs frequently after certain  precipitating factor (e.g. GI 
bleeding) 
• Median survival time is only 2 weeks 
TYPE 2 HEPATO RENAL SYNDROME  
• Characterized by a less severe and non-progressive reduction of 
GFR.  
• Associated with relatively preserved liver function. 
• The main clinical consequence of this type of HRS is refractory 
ascites, due to a lack of response to diuretic.  
• Median survival time is about 6 months. 
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CAUSES FOR HEPATORENAL SYNDROME 
Risk factors for developing HRS have been reported  based on a 
large series of  patients with cirrhosis and  ascites and, for the most part, 
are related to  renal  function. 
Three important and easily recognized risk  factors are 
1. low mean arterial  blood pressure (<80 mm  Hg), 
2. dilutional hyponatremia, and 
3. severe urinary  sodium  retention (urine sodium <5 mEq/L). 
 
Interestingly, patients with advanced liver  disease, defined by a 
high  Child-Pugh score or worsening  parameters of liver function, such 
as low albumin,  raised bilirubin,  and  increased prothrombin levels, 
are not at higher risk of   developing HRS.  
In some patients, HRS may occur  spontaneously, whereas  in 
others, it may be associated  with infections (particularly SBP), acute 
alcoholic  hepatitis, or large-volume paracentesis without albumin  
replacement. SBP  precipitates type 1 HRS in  approximately 20% of 
patients despite appropriate and  timely diagnosis, treatment, and 
resolution of infection.  Large-volume  paracentesis without albumin 
replacement  can precipitate type 1 HRS in up to  15% of patients.   
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The following is a list of risk factors  associated with the  
development of HRS in patients with  cirrhosis who are nonazotemic. 
All  measurements were  obtained after a minimum of 5 days on a low-
salt diet  and  without diuretics. 
• Low urinary sodium excretion  (<5 mEq/L)  
• Low serum sodium (dilutional hyponatremia)  
• Reduced free-water excretion after water load  
• Low mean arterial pressure 
• High plasma renin activity  
• Increased plasma norepinephrine  
• Low plasma osmolality  
• High urine osmolality 
• High serum potassium  
• Previous episodes of ascites 
• Absence of hepatomegaly 
• Presence of esophageal varices  
• Poor nutritional status  
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PATHOGENESIS  OF HEPATORENAL  SYNDROME ARE 
• Peripheral arterial vasodilation with hyperdynamic circulation 
and  renal  vasoconstriction(50). 
• Stimulation of  the  renal sympathetic nervous system (SNS)  and  
renal hypoperfusion. 
• Cardiac dysfunction contributing to the circulatory derangements                                          
• Action of different cytokines and vasoactive mediators on the 
renal  circulation  and other vascular beds. 
FACTORS INVOLVED  IN  THE  PATHOGENESIS OF   
HEPATO RENAL  SYNDROME ARE; 
• Disturbance in systemic hemodynamics (vasodilation  mainly 
splanchnic).  
• Increased   activity of vasoconstrictor systems. 
• Reduced activity of vasodilator systems.  
 
VASODILATORS                           VASOCONSTRICTORS     
Prostaglandins                                      RAAS and Sympathetic(SNS) 
Nitric oxide                                           ADH , Endothelin   
Atrial natriuritic peptide                       Adenosine,  leukotrienes 
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FIGURE : 1 
 
FIGURE : 2 
 
                                           
The RAAS and SNS are the predominant  systems  responsible 
for renal  vasoconstriction. The  activity of both systems is increased in  
patients  with  cirrhosis and ascites, and this effect is magnified in HRS.  
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In  contrast, an inverse relationship exists between the  activity of these 
two systems  and  renal plasma flow (RPF)  and the glomerular 
filtration rate (GFR)-(FIGURE-1) Endothelin  is  another  renal 
vasoconstrictor present in increased  concentration in  HRS, although 
its role in the pathogenesis of this  syndrome  is  yet to be identified.12 
Adenosine is well  known for its vasodilator  properties, although it acts 
as a  vasoconstrictor in the lungs and kidneys. Elevated  levels  of 
adenosine are more common in patients  with  heightened activity of the 
RAAS and may work  synergistically with angiotensin II to produce 
renal  vasoconstriction in HRS. This effect has also been  described 
with the powerful  renal vasoconstrictor,  leukotriene E4. 
The vasoconstricting effect of these various systems is  
antagonized by local renal  vasodilatory factors, the most important of 
which are the Prostaglandins. Perhaps the strongest evidence supporting 
their  role in renal  perfusion is  the marked decrease in Renal Blood 
flow and the GFR when nonsteroidals, medications known  to  sharply 
reduce PG levels, are administered.  
Nitric oxide (NO) is another vasodilator  believed to play an  
important role in renal perfusion. Preliminary studies,predominantly 
from animal  experiments, demonstrate that NO production is increased 
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in people with cirrhosis, although NO inhibition  does not result in renal 
vasoconstriction due to a  compensatory increase in PG synthesis. 
However, when  both NO and PG production are inhibited, marked 
renal  vasoconstriction develops. 
These findings  demonstrate that renal  vasodilators play a critical 
role in  maintaining renal perfusion, particularly in the  presence  of 
overactivity of renal vasoconstrictors. However, whether 
vasoconstrictor activity becomes the  predominant system in HRS and 
whether  reduction in  activity of the vasodilatory system contributes to 
this  have yet to be  proven.   
Various theories have been  proposed to explain the development 
of HRS in cirrhosis. The two  main theories are the arterial 
vasodilatation  theory (FIGURE-1)  and the hepatorenal reflex theory 
(FIGURE-3). The former theory not  only describes  sodium and water 
retention in cirrhosis,  but also may be the most rational  hypothesis for 
the  development of HRS. Splanchnic arteriolar vasodilatation  in  
patients with  compensated cirrhosis and portal  hypertension may be 
mediated by  factors, the  most important of which is probably NO. In 
the early phases  of portal hypertension and compensated  cirrhosis, this 
underfilling of the arterial bed causes a  decrease in the effective arterial 
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blood volume and  results in homeostatic/reflex activation of the  
endogenous vasoconstrictor systems.  
Activation of the RAAS and SNS occurs with  antidiuretic 
hormone secretion, a  later event when a more marked derangement  in   
circulatory function is present. This results in  vasoconstriction not only 
of the  renal vessels, but also in  vascular beds of the brain, muscle, 
spleen, and  extremities. The splanchnic circulation is resistant  to  these 
effects because of the continuous production of  local vasodilators such 
as NO.  
In the early phases of portal  hypertension, renal  perfusion is 
maintained within  normal or near-normal limits as the vasodilatory  
systems  antagonize the renal effects of the vasoconstrictor  systems. 
However, as  liver disease progresses in severity,  a critical level of 
vascular underfilling is  achieved. Renal  vasodilatory systems are 
unable to counteract the  maximal  activation of the endogenous 
vasoconstrictors  and/or intrarenal vasoconstrictors,  which leads to  
uncontrolled renal vasoconstriction. Support for this  hypothesis is  
provided  by studies in which the  administration of splanchnic  
vasoconstrictors combination with volume expanders results in  
improvement in arterial pressure,  RPF, and the GFR.The  alternative 
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theory proposes that renal vasoconstriction  in  HRS is unrelated to 
systemic hemodynamics but is due  to either in the synthesis  of a 
vasodilatory factor or a  hepatorenal reflex that leads to renal 
vasoconstriction.   Evidence points to the vasodilation theory as a more  
tangible explanation for the  development of HRS. 
FIGURE : 3 
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THE INTERNATIONAL ASCITES CLUB HAS DEFINED 
CRITERIA FOR THE DIAGNOSIS OF HRS.  
MAJOR  AND MINOR CRITERIA, NECESSARY ONLY FOR 
THE DIAGNOSIS, ARE AS FOLLOWS: 
  MAJOR CRITERIA  
• Chronic or acute liver disease with liver failure and portal 
hypertension 
• Low glomerular filtration rate as indicated by a serum creatinine 
of  1.5mg/dL  or a creatinine clearance of <40 mL/min 
• Absence of shock, ongoing bacterial infection, and recent 
treatment with  nephrotoxic drugs. 
• Absence of excessive fluid loss including gastrointestinal loss 
• No sustained improvement in renal function following expansion 
with 1.5 L  of  isotonic saline 
• Proteinuria of <0.5 g/d and no ultrasonagraphic evidence of renal 
Disease 
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MINOR CRITERIA 
 
• Urine volume < 500 mL/d 
• Urine sodium >10 mmoL/d 
• Urine osmolality >plasma osmolality 
• Urine red cell count < 50 per high power field 
• Serum sodium _<130 mmol/L 
 
Of the various complications in liver cirrhosis  including  
gastrointestinal  bleeding, ascites and hepatocellular  carcinoma, the 
rapidly progressive form of  kidney  dysfunction in cirrhosis, i.e. 
hepatorenal syndrome type  1, still carries the  worst prognosis. In the 
early 1990s,  median survival of these patients was reported  to be as  
short as two weeks(20)  and some more recent papers  indicate that, in 
terms  of prognosis, there has not been  much progress since(6). 
However, during the past  two  decades, new treatment concepts based 
on an improved  pathophysiological  understanding  of  the mechanisms  
ultimately leading to hepatorenal syndrome  (HRS) have  been 
introduced, and—very recently—a first randomized,  controlled trial 
evaluating one of these concepts (i.e.  vasoconstrictor treatment  with 
the vasopressin analogue  terlipressin) has been published in abstract 
form(48).  Despite successful drug treatment approaches, to date, the only 
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definitive  treatment of HRS type 1 is liver  transplantation or even 
combined liver/kidney  transplantation in some patients.  
The annual incidence of hepatorenal  syndrome among adults 
with ascites and cirrhosis is approximately 8%. In addition, among 
adults with cirrhosis  and  portal hypertension, 20%  develop 
hepatorenal syndrome in the first year after  diagnosis, and as many as 
40% of patients develop hepatorenal syndrome  within  5 years after 
diagnosis.1 Incidence data in children are  scarce in literature; , their  
incidence  of  hepatorenal syndrome is essentially unknown at this time. 
RACE 
People of all races who have chronic liver disease are at risk for 
HRS. 
SEX 
Frequency is equal in both sexes. 
AGE 
Most  patients with chronic liver disease are in their  fourth to 
eighth decades of  life. 
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MORTALITY/MORBIDITY 
The median survival of adults with type 1  hepatorenal syndrome 
is  estimated to be 2 weeks, and  the hospital survival of  the same 
patients is about  10%. In  contrast, the median survival of individuals 
with type 2 hepatorenal  syndrome is about 6 months.  Survival and the 
recovery of renal function  depend on the recovery of hepatic function,  
which is usually accomplished with  liver transplantation  in a minority 
of patients. About 1-7% of patients with  hepatorenal syndrome  
develop end-stage renal disease and require dialysis despite  liver 
transplantation and a recovery of  hepatic   function. 
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AIM  AND OBJECTIVE 
 
1. To assess the resistivity index of cirrhotics with ascites 
& cirrhotics  without ascites. 
2. To correlate with clinical status and s.creatinine levels. 
3. To detect persons with Increased resistive index in the 
presence of normal renal parameters . And to identify a 
subset of patients at higher risk of development of  
HRS.  
4. To find out the usefulness and applicability of this 
methodology. 
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MATERIALS AND METHODS 
STUDY POPULATION 
                A   total of  92  patients  in which  there were 75 cases which 
included cirrhosis  with  ascites, cirrhosis  without ascites  and 17 
controls which included  fatty liver and  healthy individuals  formed the 
study group.  
Patients were selected for the study who satisfied all the inclusion 
and exclusion criteria. Written consent was obtained from all the 
patients participating  in  the study. All patients and controls were  not 
from a  single ethnic background. 
STUDY DESIGN 
Single centre, descriptive, cross sectional, non-interventional 
study. 
INCLUSION CRITERIA     
Patients attending Medical Gastroenterology clinic and General 
Medicine Wards  with  Chronic Liver Disease  with or  with out 
decompensation. 
 
35 
 
EXCLUSION CRITERIA 
1. Preexisting renal parenchymal disease   
2. Other  causes of  renal vasoconstriction 
• Drug-induced renal failure( e.g. aminoglycosides and   
NSAIDs) 
• Glomerulonephritis 
• Prerenal failure 
• Sepsis  
• Acute tubular necrosis 
 SAMPLE SIZE 
92 
MATERIALS AND METHODS 
          We  prospectively studied 92 patients.   
Detailed clinical  history was  taken from each patients  and a 
complete review of  their case notes performed. A complete clinical  
examination of the abdomen was done for each patient. Blood 
investigations were done. USG abdomen (FIGURE-4) was done which 
detects the liver echoes, ascitic fluid, kidney size .Portal  Doppler  was 
done to elicit portal hypertension picture. Renal Doppler (FIGURE-5)  
was done to measure the resistivity index, pulsatality index. The RI of 
three renal vessels, obtained in three renal areas, was measured in each 
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patient by using at least three  Doppler spectra, and the mean value was 
calculated. 
LABORATORY METHODS 
In all  the selected patients the  following investigations were 
done; 
LIVER  FUNCTION TEST 
RENAL  FUNCTION TEST 
SERUM SODIUM 
USG ABDOMEN 
PORTAL  DOPPLER 
RENAL  DOPPLER 
FIGURE : 4 
                   USG ABDOMEN SHOWING BOTH THE KIDNEYS  
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FIGURE : 5 
RENAL DOPPLER SHOWING WAVE PATTERN 
 
            
STATISTICAL ANALYSIS 
The significance of difference between two proportions was 
indicated by the chi-square (x2) statistics. The significance of 
difference in mean between three  groups was calculated by student   
t-test. Variables were considered to be  significant  if   (P<0.05). 
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REVIEW OF LITERATURE 
The association between liver disease and renal failure had been 
known for more than a hundred years. Frerichs, the founder of modern 
liver pathology, reported the presence of oliguria in patients with 
ascites in 1877(30).Flint noted that in most cases of renal failure in 
cirrhosis, there were no significant histological changes in the kidneys 
at autopsy. In 1956, Hecker and Sherlock described renal failure in nine 
patients with liver disease characterised by progressive oliguria, very 
low urinary sodium excretion, hyponatraemia, but no proteinuria.(32) It 
was later established that the renal failure was functional, since the 
kidneys of these patients could be successfully transplanted to other 
patients with chronic renal failure, and the renal failure was reversible 
after liver transplantation.(33) Using clearance techniques, the hallmark 
of the HRS was found in 1967 to be severe renal vasoconstriction.(34) 
            The term “hepatorenal syndrome” was first used in 1939 to 
describe the occurrence of renal failure after biliary surgery or hepatic 
trauma. Later it was extended to other types of acute renal failure in 
liver diseases. In 1996, the International Ascites Club(2) proposed a new 
definition and diagnostic criteria for HRS, since then this term has been 
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generally accepted for the functional  renalfailure that develops in 
patients with advanced cirrhosis.11  
Renal Doppler ultrasonography 
FIGURE :6 
 
 
 
 
 
 
 
  
Hepatorenal syndrome (HRS) is characterized by renal 
vasoconstriction. Renal vasoconstriction has been documented in 
several series of  cirrhotic  patients by  Doppler ultrasound (US) 
analysis of renal arteries, showing  increased resistive  index (RI) (7)  
which is determined from the spectral waveforms and corresponds to 
the following formula: (peak systolic frequency  shift – lowest diastolic 
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frequency shift)/peak systolic frequency shift (FIGURE-6).On average, 
renal RI is  higher in cirrhotic patients compared to healthy 
individuals and high  RI (over 0.7)  can be observed in cirrhotic 
patients with serum creatinine within the  normal range(7). In 
patients without refractory ascites, RI decreases from the  hilum 
towards  the outer parenchyma, suggesting that the flow to the cortex is  
relatively preserved (7). In contrast, in patients with refractory ascites, 
RI is also increased in the  cortical vessels suggesting cortical 
vasoconstriction. Paracentesis  and albumin  infusion are followed by a 
significant decrease in renal RI (8). Liver transplantation is also followed 
by a decrease in RI (10).  
In patients with normal serum creatinine, increased RI  seems to 
be correlated with a higher risk of subsequent deterioration in renal 
function(10) . Therefore, Doppler ultrasound may be an early marker of 
renal dysfunction. In candidates for transplantation, high renal RI is 
associated with a greater risk of renal dysfunction and dialysis post-
transplantation. 
Overall, Doppler US may be useful for identifying patients at 
high risk for developing impaired renal function at an early stage. It 
may be useful for clarifying the mechanisms involved in renal 
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insufficiency. It may help to  clarify  the role of therapeutic intervention 
on renal hemodynamics.  
The intraparenchymal renal arterial RI was determined according  
Platt et al(19) and was as follows: RI equals (peak systolic frequency 
shift minus minimum diastolic frequency shift) divided by peak systolic 
frequency shift. The Doppler signal was recorded from both kidneys, 
from arcuate arteries of the corticomedullary junction, or from 
interlobar arteries along the margin of the medullary pyramids. To 
minimize sampling error, the Doppler spectrum was increased by using 
the lowest frequency-shift range possible without aliasing and  a  
low-frequency (100-MHz) wall filter. The RI of three renal vessels, 
obtained in three renal areas, was measured in each patient by 
using at least three Doppler spectra, and the mean value was 
calculated. A renal RI of 0.70 or more was considered abnormal 
and consistent with the presence of high renal vascular resistance 
and renal vasoconstriction (19)  
Early detection of renal vasoconstriction by Doppler predicts 
future  development of HRS in patients with cirrhosis. In a prospective 
study done by Platt  et al(19).  Patients with cirrhosis and  elevated renal 
resistive indices and normal renal  function have a 55%  probability for 
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developing subsequent kidney dysfunction  compared  with 6% with 
normal indices. HRS develops in 26% of patients with elevated resistive 
indices compared with 1% of those with normal  indices (P < 0.001). 
In cirrhotic patients without ascites, standard kidney function 
tests and  glomerular filtration rate (GFR) are normal . In non azotemic 
ascitic  patients, GFR is normal  or slightly reduced . Invasive methods 
have  demonstrated that intrarenal blood flow is already reduced in the 
non  ascitic phase of the disease and  progressively decreases with 
disease  evolution . Impaired renal perfusion plays a key role in sodium 
and fluid  retention and severe renal vasoconstriction leads to the 
development  of hepatorenal syndrome . 
HEMODYNAMIC FINDINGS IN HEPATORENAL SYNDROME 
Increased cardiac output 
Reduced arterial pressure 
Reduced total systemic vascular resistance 
Increased total blood volume 
Increased activity of vasoconstrictor systems 
Increased portal pressure 
Portosystemic shunting 
Reduced splanchnic vascular resistance 
Increased renal vascular resistance 
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Increased brachial and femoral artery resistance 
Increased cerebral vascular resistance 
Duplex evaluation of resistance indices represents a non-invasive 
method for estimating vascular resistance in the arterial bed 
downstream from the vessel in which they are calculated.  Experimental 
studies have clearly demonstrated that in the kidney a  linear correlation 
exists between resistance indices and decreasing organ perfusion caused 
by progressive gel microsphere embolization An interesting finding in 
the current study is the increased renal vascular resistance in 
cirrhotic  with normal kidney function. The increase in resistance 
indices is present in the non-ascitic phase of  the disease and 
becomes  more manifest after the development of  ascites. The 
significant negative  correlation between creatinine clearance and 
Pulsatality Index(PI) points to the role of renal  vasoconstriction in 
the development of cirrhotic kidney disease. However, PI is more 
accurate  in differentiating  abnormal waveforms because it takes into 
account the mean  velocity.  Sacerdoti et al(14)  demonstrated a weak 
negative correlation  between PI  and RI and creatinine clearance in 
cirrhotic adult patients  with normal kidney  function. Derangement of 
renal perfusion in   patients is related to the severity  of liver disease  as 
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evaluated with Child score. Resistance indices are higher among  class 
C patients than  class A and B. There is also a significant positive 
relationship  between  resistance indices and the Child score. 
Moreover, multiple regression  analysis reveals that the severity of liver 
disease is the factor most affecting the  levels of PI. Although it is 
known that kidney dysfunction is related to liver  derangement, no 
evidence exists of a direct relationship between liver and kidney  
function.  
In experimental models of cirrhosis, portal hypertension 
correlates with the reduction in GFR. The degree of portal hypertension 
was  evaluated in our patients by duplex Doppler parameters and a 
matrix  factor was extracted by regression analysis.  
Renal vasoconstriction evaluated by these indices is correlated 
with Child score which quantitatively measures the hepatic  function  in 
cirrhosis. 
Hence monitoring renal resistance  indices, is an easy non-
invasive method  for studying the  very early renal  hemodynamic 
alterations in  cirrhosis. 
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TWO SIMILAR STUDIES  WERE SHOWN HERE 
 
STUDY : 1 
 
INTRA RENAL RESISTANCE INDEX FOR THE 
ASSESSMENT OF EARLY  RENAL FUNCTION IMPAIRMENT 
IN PATIENTS WITH LIVER  CIRRHOSIS. EUR J MED RES 
2008 AUG 18;13(8);383-7 
Renovascular vasoconstriction in patients with hepatorenal 
syndrome can be  quantified by the renal arterial resistance index (RI). 
The study group investigated  the value of  RI measurement in detection 
of renal function impairment in patients  with different  stages of 
chronic liver disease.   
Subjects were divided into 4 groups containing 21 patients with 
liver cirrhosis and ascites, 25 patients with liver  cirrhosis without 
ascites, 35 patients with fatty liver disease and 78 control  subjects. All 
patients underwent abdominal ultrasound examination with renal RI 
measurement and correlation with laboratory results for renal function. 
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It was found that  RI was significantly higher in ascitic patients 
compared to non-ascitic patients  (0.74 vs. 0.67, p<0.01) and in non-
ascitic patients with liver cirrhosis than in  control subjects (0.67 vs. 
0.62, p<0.01). 48% (19/40) of patients with liver  cirrhosis and normal 
serum creatinine concentration showed elevated RI levels. There were 
no significant differences in RI levels between patients  with fatty liver  
disease and controls (0.63 vs. 0.62). Intrarenal RI measurement is a 
predictor of renal vasoconstriction and serves to detect early renal 
function impairment in cirrhotic patients. The diagnosis of elevated RI 
may be taken into  account in the clinical management of these patients. 
STUDY : 2 
RENAL BLOOD FLOW  DETECTION  WITH  DOPPLER 
ULTRASONOGRAPHY IN  PATIENTS WITH HEPATIC 
CIRRHOSIS  
Harika Çelebi, MD; Emir Dönder, MD; Hüseyin Çeliker, MD  Arch 
Intern Med. 1997;157(5):564-566.  
Hepatorenal syndrome, a well-recognized complication of established 
liver disease,  is characterized by early renal vasoconstriction before 
clinically recognized renal  disease. Renal vasoconstriction causes 
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increased renal vascular resistance, which  can be detected 
noninvasively by Doppler ultrasonography.  
OBJECTIVE 
To detect early renal hemodynamic changes in patients with 
hepatic cirrhosis who  had clinically normal renal functions.  In the 
study there were Twenty patients with hepatic cirrhosis and ascites, 11 
patients with hepatic  cirrhosis without ascites, and 23 healthy control 
subjects. In was found that  all cirrhotic patients had  normal serum urea 
nitrogen and creatinine values.  Peak systolic, peak diastolic, and mean 
flow velocities; pulsatile index; resistive index; and peak systolic 
velocity/peak diastolic velocity ratio as measured by renal  Doppler 
ultrasonography. It was found that Peak diastolic flow velocity was 
significantly lower in cirrhotic patients with  ascites than in cirrhotic 
patients without ascites and control subjects (P<.02 and P<.004, 
respectively), but the peak systolic flow velocity/peak diastolic flow 
velocity ratio (P<.007 and P<.001, respectively), pulsatile index 
(P<.007 and P<.001, respectively), and resistive index (P<.007 and 
P<.001, respectively) were significantly higher in cirrhotic patients with 
ascites than in cirrhotic patients  without ascites and controls.  This lead 
the research group to conclude that Renal Doppler ultrasonography can 
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noninvasively identify a subgroup of  nonazotemic patients with hepatic 
cirrhosis who are at high risk for subsequent  development of renal 
dysfunction and hepatorenal syndrome. Arch Intern Med.1997;157:564-
566  
GENERAL RECOMMENDATIONS FOR THE RATIONAL 
MEDICAL THERAPY OF ASCITES IN  PATIENTS WITH 
CIRRHOSIS 
1. Patients who develop moderate ascites for the first time should 
receive an aldosterone antagonist such as spironolactone alone, 
starting from 100 mg/day increasing to maximum of 400 mg/day 
(level 1). In patients who do  not respond to aldosterone 
antagonists, as defined by a reduction of  body weight of less than 
2 kg/wk, or in patients who develop hyperkalemia, furosemide 
should be added at an increasing dose from 40 mg/day to a 
maximum of 160 mg/day(level 1). Patients should undergo regular 
clinical and biochemical monitoring during the first month of 
treatment. 
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2. Patients who develop recurrent moderate ascites should be treated 
with a combination of an aldosterone antagonist plus furosemide, 
whose dose should be  increased sequentially as above. 
3. The maximum recommended weight loss during diuretic therapy 
should be, 0.5 kg/day in patients without edema,and 1 kg/day in 
patients with significant edema. 
4. The goal of long-term treatment is to keep patients free of ascites 
with the minimum dose of diuretics. Therefore, once the ascites 
has been largely resolved the dose of diuretics should be reduced 
or discontinued if possible.  
5. Patients who are not responsive to top diuretic doses or those who 
develop serious complications under diuretic treatment should be 
checked for refractory ascites. First of all, the compliance with 
low-sodium diet should be checked by determining urine sodium 
excretion in these patients. 
6. Since therapeutic paracentesis results in a more rapid resolution of 
ascites with a lower incidence of complications compared with 
diuretic treatment, paracentesis is the first-line therapy in patients 
with tense ascites. 
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7. Therapeutic paracentesis is also the first-line treatment in patients 
with refractory ascites. 
8. Therapeutic paracentesis should be completed in a single session. 
9. Since the removal of a large amount of ascitic fluid can cause 
impairment of circulatory function leading to renal failure and/or 
hyponatremia, it is necessary to prevent these circulatory changes. 
The best method to prevent circulatory dysfunction is the 
administration of albumin at a dose of 8 g/L of ascitic fluid 
removed.  
10. In patients undergoing therapeutic paracentesis of half L of 
ascites, the use of alternative plasma expanders is not 
recommended since they are less effective in preventing 
postparacentesis circulatory dysfunction. 
11. After therapeutic paracentesis, patients should receive the 
minimum dose of  diuretics necessary to prevent the 
reaccumulation of ascites 
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Prevention 
The risk of death in hepatorenal syndrome is very high; 
consequently, there is a significant emphasis on the identification of 
patients who are at risk for HRS, and  prevention of triggers for onset of 
HRS. As infection (specifically  spontaneous bacterial peritonitis) and 
gastrointestinal hemorrhage are both  complications in  individuals with 
cirrhosis, and are common triggers for HRS, specific care is made  in 
early identification and treatment of cirrhotics with these  complications 
to prevent HRS.[5] Some of the triggers for HRS are induced by  
treatment of ascites and can be preventable. The aggressive use of 
diuretic medications should be avoided. In addition, many medications 
that are either used to treat cirrhotic complications (such as some 
antibiotics) or other conditions may cause sufficient impairment in 
renal function in the cirrhotic to lead to HRS.[4][5] Also, large volume 
paracentesis—which is the removal of ascites fluid from the abdomen 
using a needle or catheter in order to relieve  discomfort—may cause 
enough alteration in hemodynamics to precipitate HRS,  and should be 
avoided in individuals at risk. The concomitant infusion of  albumin can 
avert the circulatory dysfunction that occurs after large volume  
paracentesis, and may prevent HRS.[5] Conversely, in individuals with 
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very tense  ascites, it has been hypothesized that removal of ascitic fluid 
may improve renal function if it decreases the pressure on the renal 
veins.[5] 
FIGURE : 7 
Attempts at reversing HRS have required intervening on the 
individual steps 
 
PITFALLS 
• Nephrotoxic agents should be avoided because of the risk of 
developing HRS. Drugs that are commonly associated with HRS 
in patients with cirrhosis are nonsteroidals, aspirin, 
aminoglycosides, and iodine-containing contrast agents.  
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• A diagnostic paracentesis should be considered in all patients 
who have cirrhosis with ascites who develop HRS, to exclude the 
presence of SBP. Few, if any, contraindications exist for a 
diagnostic paracentesis, and the use of empiric antibiotics in this 
situation is not justified.  
• Other causes of renal failure need to be considered in the 
differential diagnosis, and assuming that all patients who have 
cirrhosis with renal impairment have HRS is wrong. A 
standardized approach to the evaluation of renal failure not only 
confirms HRS, it also identifies conditions that may be 
reversible.  
• In patients with cirrhosis who have decompensated, evaluation of 
candidacy for liver transplantation should be performed before 
the onset of HRS. This helps physicians decide/stratify the 
aggressiveness of treatment when HRS develops. Liver transplant 
evaluation in a hospitalized patient with type 1 HRS may be too 
late, given the dearth of donors. 
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RESULTS AND OBSERVATION: 
AGEWISE CLASSIFICATION; 
FIGURE : 8 
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TABLE : 1 
 
AGE IN YRS CIRRHOSIS  WITH ASCITES 
CIRRHOSIS 
WITHOUT 
ASCITES 
HEALTHY 
30-40 01(1%) 01(1%) 0 
40-50 21(23%) 10(12%) 06(05%) 
50-60 23(25%) 14(18%) 09(08%) 
60-70 04(4%) 01(1%) 02(2%) 
 
 
Among 92, 25%  of cirrhosis with ascites patients falls in the age 
group  of  50 to 60 years,23% are in the age group of 40 to 50 years. 
Can J Gastroenterol. 2004 Feb;18(2):121-2.  
Am J Gastroenterol. 2002 Aug;97(8):1868-70.  
Above  mentioned study  shows mean age of 39 to 63 years. In 
our study  mean  age group falls between 33  to 64 years (figure-8). 
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SEXWISE CLASSIFICATION 
FIGURE : 9 
77
15
MALES
FEMALES
 
 
TABLE : 2 
MALES           77    84 % 
FEMALES         15    16 %      
 
Can J Gastroenterol. 2004 Feb;18(2):121-2.  
Am J Gastroenterol. 2002 Aug;97(8):1868-70.  
 
Out of the  total of 92 patients 77 were males,15 were females.  
In the above  mentioned  study  67% were males compared to our study 
(figure-9) which shows 84%   males .    
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ALCOHOLIC VS NON ALCOHOLIC 
FIGURE : 10 
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TABLE :3 
 MALES FEMALES 
ALCOHOLIC 48(52%) 07(8%) 
NON ALCOHOLIC 19(21%) 06(6%) 
HEALTHY 10(11%) 02(2%) 
 
Out of the  77 males 52%were alcoholic and 8% of females also 
were alcoholic. 
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CIRRHOSIS WITH  ASCITES/NONASCITES 
FIGURE : 11 
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TABLE : 4 
CIRRHOSIS/ASCITES 49(53%) 
CIRRHOSIS/NON ASCITES 26(28%) 
HEALTHY 17(18%) 
 
Total 92 patients,  49 were  cirrhosis with ascites  patients, 26 
were   cirrhosis  without  ascites   patients,17 healthy which includes 
fatty liver also.    
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CLASSIFICATION  BASED ON CAUSES 
FIGURE : 12 
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TABLE : 5 
ALCOHOLIC CIRRHOSIS 57 62% 
HBS 16 17% 
CRYPTOGENIC 7 8% 
HEALTHY 12 13% 
 
Alcoholic cirrhosis is 62%,17% were hepatitis B positive and 8% 
were of cryptogenic cause. 
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              RESISTIVITY INDEX IN VARIOUS GROUPS 
 
FIGURE : 13 
 
TABLE : 6 
      
GROUPS CATAGORIES ELEVATED RI NORMAL RI 
A CIRRHOSIS/ASCITES 45 04 
B CIRRHOSIS/NON 
ASCITES  
18 08 
C FATTY 
LIVER/HEALTHY 
02 15 
 
B 
18/08 
C 
2/15 
          A 
       45/04 
      TOTAL 
       PATIENTS 
           92 
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COMPARING  RESISTIVITY INDICES 
FIGURE : 14 
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A renal RI of 0.70 or more was considered abnormal according to 
the study of Platt JF, Ellis JH, Rubin JM, Merion RM, Lucey  
MR: Renal duplex Doppler ultrasonography: A noninvasive predictor 
of kidney dysfunction hepatorenal failure in liver disease.  Hepatology 
20:362 –369,1994 
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TABLE : 7 
 RI 
CIRRHOSIS/ASCITES >0.87 
CIRRHOSIS/NON ASCITES >0.76 
HEALTHY >0.64 
 
In our study(figure-13) Resistivity index is increased in both 
cirrhosis with ascites and without ascites. So early phase itself shows 
increased RI. In  Eur J Med Res. 2008 Aug 18;13(8):383-7, RI was 
significantly higher in ascitic patients compared to non-ascitic 
patients (0.74 vs. 0.67, p<0.01) and in non-ascitic patients with liver 
cirrhosis than in control subjects (0.67 vs. 0.62, p<0.01). In our study  
RI was significantly higher in ascitic patients compared to non-ascitic 
patients (0.87 vs. 0.76, p<0.01) and in non-ascitic patients with liver 
cirrhosis than in control subjects (0.76 vs. 0.64, p<0.001) . 
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PROBABILITY OF HRS IN CIRRHOSIS  WITH ASCITES 
FIGURE : 15 
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TABLE : 8 
CIRRHOSIS WITH ASCITES   49 patients 
 PROBABILITY OF HEPATORENAL   13 patients 
 
Considering various studies   the probability of HRS in cirrhosis 
with ascites  is 26% .        
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EXPECTED MORTALITY 1YR&5YR 
FIGURE : 16 
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TABLE: 9 
 
 
 
 
 
WITH ASCITES  49 
1 YR MORTALITY 20% 10 
5 YR MORTALITY 40% 20 
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PULSATALITY INDEX 
FIGURE : 17 
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   TABLE : 10 
 PI 
CIRRHOSIS/ASCITES >1.12 
CIRRHOSIS/NON ASCITES >1.01 
HEALTHY >0.08 
 
PI is  increased in cirrhosis with ascites patients  compared to 
cirrhotics without ascites (1.12 vs1.02), cirrhotics without ascites and 
healthy (1.02vs0.08). 
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55%  CIRRHOSIS WITH ELEVATED RI AND NORMAL 
RENAL FUNCTION DEVELOPS SUBSEQUENT KIDNEY 
DYSFUNCTION 
TABLE :11 
 
TOTAL NO OF 
PATIENTS 
92 PATIENTS  
CIRRHOTICS WITH 
ELEVATED   RI 
63PATIENTS 35 PATIENTS 
 
FIGURE  : 18 
 
92(TOTAL
PATIENTS)  
63(CIRRHO
TICS) 
35(KIDNEY 
DYS) 
69 
 
PORTAL DOPPLER RESULT       RENAL DOPPLER RESULT 
          
        
 
 
 
 
 
 
 
 
  RENAL DOPPLER RESULT        RENAL DOPPLER  RESULT        
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RESULTS 
In my study, I found that 
Elevated RI 65/92=71% 
Normal RI 27/92=29% 
 
GROUPS CATAGORIES ELEVATED 
RI 
NORMAL 
RI 
A CIRRHOSIS/ASCITES 45 04 
B CIRRHOSIS/NON ASCITES  18 08 
C FATTY LIVER/HEALTHY 02 15 
     
Comparing A and B groups that is cirrhosis with ascites 
(A),cirrhosis without ascites (B) 
GROUPS CATAGORIES ELEVATED RI NORMAL RI 
       A CIRRHOSIS/ASCITES 45 4 
       B CIRRHOSIS/NON 
ASCITES 
18 8 
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GROUPS  ELEVATED RI NORMAL RI 
A 
OBSERVED 45 4 
EXPECTED 41 8 
B 
OBSERVED 18 8 
EXPECTED 22 4 
     
 X2 =E (observed-expected)2   /expected+(observed-   expected)2   
/expected  
 
             X2 =E (45-41)2/41+(4-8)2/8+(18-22)2/22+(8-4)2/4 
                 = 0.39+2+0.72+4 
                   =7.11  
                 P VALUE<.01     
Comparing B group and C group that is cirrhosis without ascites 
(B), fatty liver/healthy(C). 
GROUPS CATAGORIES ELEVATED  RI NORMAL RI 
        B 
 
CIRRHOSIS 
WITHOUT 
ASCITES 
18 8 
        C FATTY LIVER 
HEALTHY 
2 15 
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GROUPS  ELEVATED RI NORMAL RI 
B 
OBSERVED 18 8 
EXPECTED 12 14 
C 
OBSERVED 2 15 
EXPECTED 8 9 
 
X2 =E (observed-expected)2   /expected+(observed-    expected)2   
/expected   
X2 =E(18-12)2 /12 +(8-14)2/14+(2-8)2/8+(15-92)/9 
X2=3+2.5+4.5+4 
=14  
P  VALUE  <.001 
 
In our study  RI was significantly higher in ascitic patients 
compared to non-ascitic patients (0.87 vs. 0.76, p<0.01) and in non-
ascitic patients with liver cirrhosis than in control subjects (0.76 vs. 
0.64, p<0.001) .  
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DISCUSSION 
 
As the majority of individuals with hepatorenal syndrome have 
cirrhosis, much of the epidemiological data on HRS comes from the 
cirrhotic population. The condition is quite common: approximately 
10% of individuals admitted to hospital with ascites have HRS.[57] A 
retrospective case series of cirrhotic patients treated with terlipressin 
suggested that 20.0% of acute renal failure in cirrhotics was due to type 
1 HRS, and 6.6% was due to type 2 HRS It is estimated that 18% of 
individuals with cirrhosis and ascites will develop HRS within one year 
of their diagnosis with cirrhosis, and 39% of these individuals will 
develop HRS within five years of diagnosis.[57] 
The mean age was 51.8 +/- 12.1 yr, and 67% were male as per 
the study on Hepatorenal syndrome: diagnostic accuracy, clinical 
features, and outcome in a tertiary care center. Watt K, Uhanova J, 
Minuk GY. Liver Diseases Unit, University of Manitoba, Winnipeg, 
Canada.Comment in: Can J Gastroenterol. 2004 Feb;18(2):121-2. 
Am J Gastroenterol. 2002 Aug;97(8):1868-70.   
In our  study 92 patients were studied including cirrhosis with  
ascites(49),without  ascites(26),fatty liver and healthy individuals(17). 
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Many of  them are in the fourth (40%) and fifth (51%) decades. 
Males (84%)   are  more  common  than  females (16%), whereas in the 
above study by university of Canada, percentage of females was  
higher. 60% were alcoholic and 25% were non alcoholic. Of the various  
causes  apart from alcoholic , 17% were hepatitis B positive, 8%  were  
cryptogenic,13% were healthy.  
According to the study by Recommendations available for 
managing ascites, SBP and hepatorenal syndrome 3. August 2010 05:53  
"It is estimated that almost 60 percent of cirrhotic patients develop 
ascites within 10 years of their disease, which is a huge proportion of 
patient .In our  study  49 (53%) were  cirrhosis with ascites  patients, 26 
(28%) were   cirrhosis  without  ascites   patients, 17 (18%) healthy 
which includes fatty liver also.   
Doppler sonography is performed to determine the intrarenal 
arteriolar vascular resistance, defined as the resistive index (RI). The 
reference range for RI is 0.7 or lower. The RI can be a more sensitive 
parameter than the creatinine clearance. Renal duplex Doppler 
ultrasonography can non invasively identify a subgroup of non 
azotemic patients with liver disease that is at significantly higher risk 
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for subsequent development of kidney dysfunction and the hepatorenal 
syndrome. (Hepatology 1994;20:362–369.) 
Out of the 49 cirrhosis with ascites  patients  45  were showing  
elevated resistivity  index, 4 were within normal range. Among 26  
cirrhosis without ascites patients, 18 were showing   elevated  resistivity  
index, 8 were within normal range. Resistivity indices were increased in 
both  cirrhosis with and without ascites. Cirrhosis with ascites=>0.87 
Cirrhosis without  ascites=>0.76 Fatty liver and healthy=>0.64.In the 
study by  Eur J Med Res. 2008 Aug 18;13(8):383-7, RI was 
significantly higher in ascitic patients compared to non-ascitic 
patients (0.74 vs. 0.67, p<0.01) and in non-ascitic patients with liver 
cirrhosis than in control subjects (0.67 vs. 0.62, p<0.01). 
In our study  RI was significantly higher in ascitic patients 
compared to non-ascitic patients (0.87 vs. 0.76, p<0.01) and in non-
ascitic patients with liver cirrhosis than in control subjects (0.76 vs. 
0.64, p<0.001) .  
Renal vascular resistance indices evaluated by duplex Doppler 
ultrasonography are already increased in the early phase of the disease. 
Development of ascites is associated with a further increase in the 
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resistance indices. Renal vasoconstriction evaluated by these indices is 
correlated with Child score which quantitatively measures the hepatic 
function in cirrhosis.  
PI is also increased in cirrhosis with ascites patients  compared to 
cirrhotics without ascites(1.12 vs1.02), cirrhotics without ascites  
compared to healthy (1.02vs0.08). 26% of cirrhosis with ascites patients 
later tends to develop  HRS.   
55% cirrhosis with elevated RI and normal renal function 
develops subsequent  kidney dysfunction that is 35  patients out of 92 
patients. 
We conclude that patients with cirrhosis are at risk of renal 
deterioration, which can not be detected by serum urea, creatinine, and 
glomerular filtration rate. The increase of RI is associated with the 
progress of hepatocellular disease, and also the development of ascites 
and portal hypertension. Hence, monitoring  RI is a non-invasive means 
of studying early renal hemodynamic alteration in  cirrhosis. 
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CONCLUSION 
 
1. We conclude that in cirrhotic, renal vascular resistance 
indices  evaluated  by  duplex Doppler ultrasonography are 
already increased in the early  phase of  the disease. 
2. Development of ascites is associated with a further increase 
in the  resistance   indices. 
3. Renal vasoconstriction evaluated by these indices is 
correlated with Child score  which quantitatively measures 
the hepatic function in cirrhosis  
4. Intrarenal RI measurement is a predictor of renal 
vasoconstriction and  serves to detect early renal function 
impairment in cirrhotic patients.  
5. The diagnosis of elevated RI may be taken into account in 
the clinical  management of these patients. 
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PROFORMA 
Name:    Age/Sex:   IP No: 
Address:   Presenting complaints: 
Abdominal distension : Yes/ No Duration:     days/ months 
Onset : Rapid/ Insidious, Progressive/ Non-progressive 
Leg swelling   :Yes/ No Duration:  days/ months               
Decreased urine output :Yes/ No Duration:  days/ months 
Anuria  : Yes/ No 
Jaundice   : Yes/ No Duration:  days/ months 
Progressive/ Non-progressive 
Encephalopathy  : Grade I    /     II      /    III     /       IV 
Bleeding Tendency  : Yes/ No 
UGI bleed   : Recent/ Remote Duration:          days/ months 
    Amount    Giddiness:          Yes/ No 
Malena   : Yes/ No       Color:          Black/ Maroon 
Other symptoms  : 
Past History   :   
UGI Bleed   : Yes/ No Duration: No. of episodes  
Jaundice   : Yes/ No   
Abdominal Surgeries : Yes/ No Blood transfusions: Yes/ No  
Tattoo    : Yes/ No Sexual contact : Yes/ No 
Personal History: 
Alcohol intake  :  Duration: Years  Amount:        ml/day 
     Frequency:  Daily/ Weekly – / Occasional 
Smoking   :  Yes/ No Duration: 
Vaccination status  : Complete/ Incomplete/ No 
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Examination   : 
Jaundice: Yes/ No  Pallor: Yes/ No  
Signs of CLD:  Spider nevi/ parotid enlargement/ gynecomastia/  
    testicular atrophy/ sparse axillary hair / Dupuytren  
    contracture 
Avitaminosis:  Yes/ No  
Abdomen: 
Hepatomegaly:  Yes/ No Size: Surface: Borders: Span:   
Splenomegaly: Yes/ No Size:  
Free fluid : Minimal/ Moderate/ Tense  Tenderness: Present/ Absent 
Investigations: 
TC:    DC: N/L/E: 
Platelet count:  ESR: 
Blood urea       
Sr. Creatinine       
Blood sugar       
Sr. Sodium       
LFT       
AST       
ALT       
SAP       
STB       
Direct       
STP       
ALBUMIN       
 
92 
 
USG abdomen: 
Liver: 
PV: 
Spleen: 
Kidneys 
Portal Doppler: 
Liver: 
PV: 
Spleen: 
Resistive Index: 
Peak systolic velocities: 
Peak diastolic velocities: 
Mean flow velocities: 
Pulsatile index: 
Resistive index: 
Peak systolic velocity/peak diastolic velocity ratio 
Outcome: Follow-up: 
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SL 
NO 
 
AGE 
 
SEX 
 
CAUSE 
 
ASC 
ITES 
 
U.O 
 
S.Na 
 
LFT 
 
UREA 
 
CREAT 
ININE 
 
USG 
ABD 
 
PORTAL 
DOPPLER 
 
R.I 
 
P.I 
1 57 M ALC 
CIRR 
Y Nl 138 RSD NL NL DCLD 
ASC 
PHT 0.76 1.12 
2 51 M ALC 
CIRR 
Y Nl 134 RSD NL NL DCLD
ASC 
PHT 0.76 1.07 
3 53 M ALC 
CIRR 
Y Nl 132 RSD NL NL DCLD
ASC 
PHT 0.81 1.38 
4 33 M HBS 
CIRR 
N Nl 136 RSD NL NL CLD CLD 0.63 1.00 
5 46 M ALC 
CIRR 
Y Nl 131 RSD NL NL DCLD
ASC 
PHT 0.77 1.21 
6 52 M ALC 
CIRR 
N Nl 137 RSD NL NL CLD CLD 0.77 1.07 
7 43 M ALC 
CIRR 
Y Nl 140 RSD NL NL DCLD
ASC 
PHT 0.82 1.42 
8 49 M ALC 
CIRR 
N Nl 137 RSD NL NL CLD CLD 0.75 1.01 
9 50 M ALC 
CIRR 
Y Nl 130 RSD NL NL DCLD
ASC 
PHT 0.64 1.24 
10 54 M ALC  
CIRR 
 
N Nl 132 RSD NL NL CLD CLD 0.71 1.06 
11 43 F ALC 
CIRR 
N Nl 133 RSD NL NL CLD CLD 0.77 1.12 
12 46 M HBS 
CIRR 
Y Nl 134 RSD NL NL DCLD
ASC 
PHT 0.81 1.38 
13 48 M ALC 
CIRR 
N Nl 137 RSD NL NL CLD CLD 0.61 0.09 
14 59 M CRYPT 
CIRR 
Y Nl 140 RSD NL NL DCLD
ASC 
PHT 0.82 1.39 
15 52 M ALC 
CIRR 
N Nl 136 RSD NL NL CLD CLD 0.76 1.06 
16 56 M ALC 
CIRR 
N Nl 133 RSD NL NL CLD CLD 0.76 1.05 
17 47 M ALC 
CIRR 
Y Nl 134 RSD NL NL DCLD
ASC 
PHT 0.78 1.46 
18 44 M ALC 
CIRR 
Y Nl 137 RSD NL NL DCLD
ASC 
PHT 0.77 1.38 
19 50 F ALC  
CIRR 
 
N Nl 134 RSD NL NL CLD CLD 0.78 1.06 
20 56 M HBS 
CIRR 
N Nl 132 RSD NL NL CLD CLD 0.64 1.03 
21 51 M HBS 
CIRR 
N Nl 138 RSD NL NL CLD CLD 0.78 1.06 
22 42 M ALC 
CIRR 
Y Nl 139 RSD NL NL DCLD
ASC 
PHT 0.76 1.43 
23 46 M ALC 
CIRR 
Y Nl 138 RSD NL NL DCLD
ASC 
PHT 0.79 1.40 
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24 49 M ALC 
CIRR 
N Nl 134 RSD NL NL CLD CLD 0.79 1.07 
25 54 F ALC 
CIRR 
Y Nl 132 RSD NL NL DCLD
ASC 
PHT 0.60 1.28 
26 58 M ALC 
CIRR 
Y Nl 136 RSD NL NL DCLD
ASC 
PHT 0.82 1.34 
27 43 M CRYP 
CIRR 
N Nl 134 RSD NL NL CLD CLD 0.74 1.03 
28 59 M ALC 
CIRR 
Y Nl 137 RSD NL NL DCLD
ASC 
PHT 0.78 1.26 
29 40 F HBS 
CIRR 
N Nl 138 RSD NL NL CLD CLD 0.62 1.03 
30 41 M CRYP 
CIRR 
N Nl 134 RSD NL NL CLD CLD 0.61 1.01 
31 47 M AIC 
CIRR 
Y Nl 133 RSD NL NL DCLD
ASC 
PHT 0.78 1.42 
32 56 M HBS 
CIRR 
Y Nl 143 RSD NL NL DCLD
ASC 
PHT 0.78 1.39 
33 54 M HBS 
CIRR 
N Nl 142 RSD NL NL CLD CLD 0.73 1.02 
35 55 M ALC 
CIRR 
N Nl 132 RSD NL NL CLD CLD 0.72 1.01 
36 34 F CRYP 
CIRR 
Y Nl 136 RSD NL NL DCLD
ASC 
PHT 0.78 1.38 
37 60 M ALC 
CIRR 
Y Nl 139 RSD NL NL DCLD
ASC 
PHT 0.76 1.43 
38 45 M ALC 
CIRR 
Y Nl 140 RSD NL NL DCLD
ASC 
PHT 0.78 1.47 
39 55 M HBS 
CIRR 
N Nl 134 RSD NL NL CLD CLD 0.61 1 
40 58 F ALC 
CIRR 
N Nl 133 RSD NL NL CLD CLD 0.79 1.06 
41 47 M ALC 
CIRR 
Y Nl 135 RSD NL NL DCLD
ASC
PHT 0.78 1.46 
42 40 M HBS 
CIRR 
Y Nl 136 RSD NL NL DCLD
ASC 
PHT 0.62 1.42 
43 49 M ALC 
FAT. 
LIV 
N Nl 141 NL NL NL CLD CLD 0.62 0.83 
44 58 F ALC 
CIRR 
Y Nl 138 RSD NL NL DCLD
ASC 
PHT 0.82 1.46 
45 53 M ALC 
FAT. 
LIV 
N Nl 132 NL NL NL CLD NL 0.63 0.86 
46 47 M ALC 
CIRR 
Y Nl 131 RSD NL NL DCLD
ASC 
PHT 0.76 1.12 
47 50 M ALC 
CIRR 
N Nl 142 RSD NL NL CLD CLD 0.71 1.07 
48 43 M CRYP 
CIRR 
N Nl 134 RSD NL NL CLD CLD 0.72 1.00 
49 40 M ALC 
CIRR 
Y Nl 132 RSD NL NL DCLD
ASC 
PHT 0.81 1.21 
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50 52 M ALC 
FAT 
LIV 
N Nl 141 NL NL NL NL NL 0.64 0.82 
51 58 F HBS 
CIRR 
Y Nl 136 RSD NL NL DCLD
ASC 
PHT 0.80 1.13 
52 45 M HBS 
CIRR 
Y Nl 137 RSD NL NL DCLD
ASC 
PHT 0.83 1.35 
53 61 M ALC 
CIRR 
N Nl 134 RSD NL NL CLD CLD 0.71 0.91 
54 47 M ALC 
CIRR 
Y Nl 138 RSD NL NL DCLD
ASC
PHT 0.80 1.39 
55 46 M ALC 
CIRR 
Y Nl 133 RSD NL NL DCLD
ASC 
PHT 0.84 1.37 
56 58 F ALC 
CIRR 
Y Nl 132 RSD NL NL DCLD
ASC 
PHT 0.83 1.43 
57 57 M ALC 
CIRR 
Y Nl 136 RSD NL NL DCLD
ASC 
PHT 0.77 1.40 
58 51 M HBS 
CIRR 
Y Nl 144 RSD NL NL DCLD
ASC 
PHT 0.79 1.38 
59 53 M ALC 
CIRR 
Y Nl 137 RSD NL NL DCLD
ASC 
PHT 0.79 1.28 
60 56 M ALC 
CIRR 
Y Nl 135 RSD NL NL DCLD
ASC 
PHT 0.77 1.23 
61 52 F HBS 
CIRR 
Y Nl 140 RSD NL NL DCLD
ASC 
PHT 0.82 1.32 
62 47 M ALC 
CIRR 
Y Nl 130 RSD NL NL DCLD
ASC 
PHT 0.80 1.65 
63 57 M ALC 
CIRR 
Y Nl 132 RSD NL NL DCLD
ASC 
PHT 0.81 1.46 
64 49 M CRYP 
CIRR 
Y Nl 135 RSD NL NL DCLD
ASC 
PHT 0.77 1.44 
65 44 M HBS 
CIRR 
Y Nl 141 RSD NL NL DCLD
ASC 
PHT 0.64 1.43 
66 58 M ALC 
FAT 
LIV 
N Nl 139 NL NL NL NL NL 0.62 0.91 
67 56 F HBS 
CIRR 
Y Nl 134 RSD NL NL DCLD
ASC 
PHT 0.81 1.12 
68 43 M ALC 
CIRR 
Y Nl 138 RSD NL NL DCLD
ASC 
PHT 0.79 1.45 
69 41 M CRYP 
CIRR 
N Nl 135 RSD NL NL CLD CLD 0.77 1.01 
70 57 M ALC 
FAT. 
LIV 
N Nl 138 NL NL NL CLD CLD 0.64 0.82 
71 60 F ALC 
CIRR 
Y Nl 140 RSD NL NL DCLD
ASC 
PHT 0.79 1.37 
72 56 M ALC 
CIRR 
Y Nl 130 RSD NL NL DCLD
ASC 
PHT 0.81 1.45 
96 
 
73 49 M CRYP 
CIRR 
N Nl 131 RSD NL NL CLD CLD 0.70 1 
74 53 F HBS 
CIRR 
N Nl 135 RSD NL NL CLD CLD 0.71 1.01 
75 55 M ALC 
CIRR 
Y Nl 139 RSD NL NL DCLD
ASC 
PHT 0.77 1.37 
76 64 M ALC 
CIRR 
Y Nl 134 RSD NL NL DCLD
ASC 
PHT 0.80 1.43 
77 42 M ALC 
CIRR 
Y Nl 142 RSD NL NL DCLD
ASC 
PHT 0.87 1.42 
78 55 M ALC 
CIRR 
Y Nl 130 RSD NL NL DCLD
ASC 
PHT 0.77 1.33 
79 47 M HBS 
CIRR 
N Nl 135 RSD NL NL CLD CLD 0.76 1.02 
80 61 M ALC 
CIRR 
Y Nl 137 RSD NL NL DCLD
ASC 
PHT 0.78 1.56 
81 50 M FAT. 
LIV 
N NL 130 NL NL NL NL NL 0.62 1.03 
82 60 M HEALT
HY 
N NL 132 NL NL NL NL NL 0.60 0.82 
83 58 M HEALT
HY 
N NL 138 NL NL NL NL NL 0.58 0.81 
84 47 F FAT. 
LIV 
N NL 136 NL NL NL NL NL 0.59 1.00 
85 49 M HEALT
HY 
N NL 140 NL NL NL NL NL 0.58 0.80 
86 44 M HEALT
HY 
N NL 138 NL NL NL NL NL 0.56 0.83 
87 57 M FAT. 
LIV 
N NL 135 NL NL NL NL NL 0.61 1.01 
88 59 M HEALT
HY 
N NL 137 NL NL NL NL NL 0.63 0.80 
89 60 M HEALT
HY 
N NL 136 NL NL NL NL NL 0.64 0.82 
90 42 F FAT. 
LIV 
N NL 133 NL NL NL NL NL 0.66 0.89 
91 53 M HEALT
HY 
N NL 143 NL NL NL NL NL 0.60 0.93 
92 46 M FAT. 
LIV 
N NL 140 NL NL NL NL NL 0.67 0.92 
.  
ABBREVIATIONS 
HRS-HEPATORENAL SYNDROME. 
RI-RESISTIVITY INDEX. 
PI-PULSATALITY INDEX. 
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